The massive settlement between Moderna and Arbutus/Genevant highlights the critical value of the lipid nanoparticle (LNP) technology used in mRNA vaccines. This creates a potential investment opportunity in companies that hold key patents for drug delivery systems, as they may be poised for lucrative licensing deals or acquisitions.
Published on March 4
The £2.25 billion Moderna settlement has opened investors' eyes to the massive value hidden in drug delivery patents. Companies with similar technology portfolios could be sitting on untapped goldmines.
This landmark agreement sets a new precedent for patent valuations, potentially triggering a wave of lucrative licensing deals across the biotech industry as companies reassess their IP worth.
Big pharma companies may now view patent holders as prime acquisition targets, especially those with foundational delivery technologies that enable multiple therapeutic applications.
The recent multi-billion pound Moderna settlement with Arbutus and Genevant has highlighted the enormous value of lipid nanoparticle (LNP) technology patents. This landmark agreement suggests that companies holding similar drug delivery patents may be significantly undervalued and could benefit from increased licensing deals or strategic acquisitions as the market reassesses the worth of foundational biotech innovations.
This group focuses on companies that own critical patents for drug delivery systems, particularly those enabling advanced therapeutics like mRNA vaccines and gene therapies. These firms typically generate revenue through licensing their platform technologies to drug developers in exchange for royalties and milestone payments. The recent settlement establishes a new precedent for how valuable these foundational technologies can be in the biotech industry.
Each company in this collection has been carefully selected for their significant patents and expertise in drug delivery and formulation technologies. Our professional analysts identified these firms as being well-positioned to potentially benefit from the heightened focus on platform technologies following the Moderna settlement, offering tactical exposure to this high-growth, innovation-driven segment of biotechnology.
This basket's total market cap is $102.68B and is dominated by a few large-cap stocks that anchor its profile. That concentration generally tends to reduce volatility compared with small-cap-heavy baskets, offering a relatively stable exposure.
MRNA: $19.68B
BNTX: $26.10B
NTLA: $1.61B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+4
Here are a few of the assets in this group. Create an account to unlock the full list.
MODERNA INC
MRNA
Current Price
$158.25
As a leading developer of messenger RNA (mRNA) therapies and vaccines, the company's success is fundamentally tied to lipid nanoparticle (LNP) deliver...
As a leading developer of messenger RNA (mRNA) therapies and vaccines, the company's success is fundamentally tied to lipid nanoparticle (LNP) delivery systems.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+142.36%
On average, analysts expect assets in this group to grow 142.36% over the next year.
10 of 14 assets in this group are rated Buy by professional analysts.
